# Phase 1b DV281 With an Anti-PD-1 Inhibitor in NSCLC

> **NCT03326752** · PHASE1 · COMPLETED · sponsor: **Dynavax Technologies Corporation** · enrollment: 26 (actual)

## Conditions studied

- Advanced Non Small Cell Lung Cancer

## Interventions

- **DRUG:** DV281
- **DEVICE:** Breath Actuated Nebulizer
- **DRUG:** DV281 (RP2D)
- **DRUG:** Approved Anti-PD-1 Inhibitor

## Key facts

- **NCT ID:** NCT03326752
- **Lead sponsor:** Dynavax Technologies Corporation
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2017-09-20
- **Primary completion:** 2019-09-19
- **Final completion:** 2019-09-19
- **Target enrollment:** 26 (ACTUAL)
- **Last updated:** 2020-06-17


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03326752

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03326752, "Phase 1b DV281 With an Anti-PD-1 Inhibitor in NSCLC". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT03326752. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*